Clinical trial
Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell…
NCT00417807 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00417807 |
|---|---|
| Title | Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors |
| Official title | Open-label Trial of Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors (DSRCT) Expressing PDGF-R |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Refractory Desmoplastic Small Round Cell Tumors |
| Intervention type | Drug |
| Interventions | Imatinib mesilate |
| Enrollment | 9 |
| Start date | Aug 1, 2005 |
| Primary completion | Jun 1, 2009 |
| First posted | Jan 4, 2007 |
| Last update posted | Dec 24, 2010 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: